What's new

Shiva Grows

zaprjaques

zaprjaques

the boveda kid
Screenshot_20240113-123231.png

Screenshot_20240113-123215.png

my bedroom co producer overlooking the session.... i got the go ahead.
 
shiva82

shiva82

Well-known member
i'm finally going to invest in a sofa for my household , just so my cat has somewhere to sit and scratch that is more substantial than her bed and various boxes and such , that she normally uses

i was thinking ,it would be like a throne. a cat throne
 
shiva82

shiva82

Well-known member
over extended my arm twice this morning . it was fine earlier. now i have less movement as it is inflamed . excuse to smoke bigger reefers
 
pipeline

pipeline

Cannabotanist
ICMag Donor
Veteran
full


Flash freeze after a rain, going to work on unfreezing the truck today. Locks were froze last night.

Careful with your arm. I have a bit of tennis elbow, basically from over-use. I was working hard this summer mowing, watering the plants, and lifting my dog. Just have to favor it for a while. Make it a practice almost, and it should heal. Definitely try a good quality spagyric or full spectrum CBD hemp tincture. It helps to have CBD with the THC for pain relief in some cases. I try not to go too high with CBD, just a little bit to boost the medical cannabis effectiveness. I take the 1000 mg, but only use about 0.25-0.5 ml since its so strong.

Cats love couches, Meech will appriciate that. Its alright if you use the couch too. I sleep on a couch actually because my bedroom is so cold. Rocket the cat keeps it warm for me. If its cold enough, I have Bonnie at the pillow and a cat at the foot of the bed helping keep me warm.

New state bills have been released. Legeslative session is over in March, so we have to get on the ball with advocacy. These bills are all bad, even the legalization. I don't think any have home cultivation. Lots of work to do. Don't join with these corrupt authorites. "Stay back" is a good rule of thumb to go by. Even if they have a medical program, they have requirements to make sure cannabis is not deferred to unauthorized persons. Too involved, too regulated, no thank you. :smoke:



Matthew 13 NKJV​

​

The Parable of the Sower​

13 On the same day Jesus went out of the house and sat by the sea. 2 And great multitudes were gathered together to Him, so that He got into a boat and sat; and the whole multitude stood on the shore.


3 Then He spoke many things to them in parables, saying: “Behold, a sower went out to sow. 4 And as he sowed, some seed fell by the wayside; and the birds came and devoured them. 5 Some fell on stony places, where they did not have much earth; and they immediately sprang up because they had no depth of earth. 6 But when the sun was up they were scorched, and because they had no root they withered away. 7 And some fell among thorns, and the thorns sprang up and choked them. 8 But others fell on good ground and yielded a crop: some a hundredfold, some sixty, some thirty. 9 He who has ears to hear, let him hear!”


The Purpose of Parables​

10 And the disciples came and said to Him, “Why do You speak to them in parables?”


11 He answered and said to them, “Because it has been given to you to know the [a]mysteries of the kingdom of heaven, but to them it has not been given. 12 For whoever has, to him more will be given, and he will have abundance; but whoever does not have, even what he has will be taken away from him. 13 Therefore I speak to them in parables, because seeing they do not see, and hearing they do not hear, nor do they understand. 14 And in them the prophecy of Isaiah is fulfilled, which says:

‘Hearing you will hear and shall not understand,
And seeing you will see and not perceive;
15 For the hearts of this people have grown dull.
Their ears are hard of hearing,
And their eyes they have closed,
Lest they should see with their eyes and hear with their ears,
Lest they should understand with their hearts and turn,
So that I [b]should heal them.’

16 But blessed are your eyes for they see, and your ears for they hear; 17 for assuredly, I say to you that many prophets and righteous men desired to see what you see, and did not see it, and to hear what you hear, and did not hear it.


The Parable of the Sower Explained​

18 “Therefore hear the parable of the sower: 19 When anyone hears the word of the kingdom, and does not understand it, then the wicked one comes and snatches away what was sown in his heart. This is he who received seed by the wayside. 20 But he who received the seed on stony places, this is he who hears the word and immediately receives it with joy; 21 yet he has no root in himself, but endures only for a while. For when tribulation or persecution arises because of the word, immediately he stumbles. 22 Now he who received seed among the thorns is he who hears the word, and the cares of this world and the deceitfulness of riches choke the word, and he becomes unfruitful. 23 But he who received seed on the good ground is he who hears the word and understands it, who indeed bears fruit and produces: some a hundredfold, some sixty, some thirty.”


The Parable of the Wheat and the Tares​

24 Another parable He put forth to them, saying: “The kingdom of heaven is like a man who sowed good seed in his field; 25 but while men slept, his enemy came and sowed tares among the wheat and went his way. 26 But when the grain had sprouted and produced a crop, then the tares also appeared. 27 So the servants of the owner came and said to him, ‘Sir, did you not sow good seed in your field? How then does it have tares?’ 28 He said to them, ‘An enemy has done this.’ The servants said to him, ‘Do you want us then to go and gather them up?’ 29 But he said, ‘No, lest while you gather up the tares you also uproot the wheat with them. 30 Let both grow together until the harvest, and at the time of harvest I will say to the reapers, “First gather together the tares and bind them in bundles to burn them, but gather the wheat into my barn.” ’ ”


The Parable of the Mustard Seed​

31 Another parable He put forth to them, saying: “The kingdom of heaven is like a mustard seed, which a man took and sowed in his field, 32 which indeed is the least of all the seeds; but when it is grown it is greater than the herbs and becomes a tree, so that the birds of the air come and nest in its branches.”


The Parable of the Leaven​

33 Another parable He spoke to them: “The kingdom of heaven is like leaven, which a woman took and hid in three [c]measures of meal till it was all leavened.”


Prophecy and the Parables​

34 All these things Jesus spoke to the multitude in parables; and without a parable He did not speak to them, 35 that it might be fulfilled which was spoken by the prophet, saying:

“I will open My mouth in parables;
I will utter things kept secret from the foundation of the world.”

The Parable of the Tares Explained​

36 Then Jesus sent the multitude away and went into the house. And His disciples came to Him, saying, “Explain to us the parable of the tares of the field.”


37 He answered and said to them: “He who sows the good seed is the Son of Man. 38 The field is the world, the good seeds are the sons of the kingdom, but the tares are the sons of the wicked one. 39 The enemy who sowed them is the devil, the harvest is the end of the age, and the reapers are the angels. 40 Therefore as the tares are gathered and burned in the fire, so it will be at the end of this age. 41 The Son of Man will send out His angels, and they will gather out of His kingdom all things that offend, and those who practice lawlessness, 42 and will cast them into the furnace of fire. There will be wailing and gnashing of teeth. 43 Then the righteous will shine forth as the sun in the kingdom of their Father. He who has ears to hear, let him hear!


The Parable of the Hidden Treasure​

44 “Again, the kingdom of heaven is like treasure hidden in a field, which a man found and hid; and for joy over it he goes and sells all that he has and buys that field.


The Parable of the Pearl of Great Price​

45 “Again, the kingdom of heaven is like a merchant seeking beautiful pearls, 46 who, when he had found one pearl of great price, went and sold all that he had and bought it.


The Parable of the Dragnet​

47 “Again, the kingdom of heaven is like a dragnet that was cast into the sea and gathered some of every kind, 48 which, when it was full, they drew to shore; and they sat down and gathered the good into vessels, but threw the bad away. 49 So it will be at the end of the age. The angels will come forth, separate the wicked from among the just, 50 and cast them into the furnace of fire. There will be wailing and gnashing of teeth.”


51 [d]Jesus said to them, “Have you understood all these things?”

They said to Him, “Yes, [e]Lord.”


52 Then He said to them, “Therefore every [f]scribe instructed [g]concerning the kingdom of heaven is like a householder who brings out of his treasure things new and old.”


Jesus Rejected at Nazareth​

53 Now it came to pass, when Jesus had finished these parables, that He departed from there. 54 When He had come to His own country, He taught them in their synagogue, so that they were astonished and said, “Where did this Man get this wisdom and these mighty works? 55 Is this not the carpenter’s son? Is not His mother called Mary? And His brothers James, [h]Joses, Simon, and Judas? 56 And His sisters, are they not all with us? Where then did this Man get all these things?” 57 So they were offended at Him.

But Jesus said to them, “A prophet is not without honor except in his own country and in his own house.” 58 Now He did not do many mighty works there because of their unbelief.

 
shiva82

shiva82

Well-known member
my coach may be nearing retirement but he is still quick at stepping out of range . i was boxing nice and getting greedy and over reached as he stepped out of range. twice . that and hitting elbows hurts the most while boxing with gloves
 
pipeline

pipeline

Cannabotanist
ICMag Donor
Veteran
I feel bad for paying taxes to this corrupt system. War is hell.

Check it out, the Health and Human Services, Food and Drug Administion sent a letter to the DEA, and it was just released in the unredacted form. Check out these condemning statements. The open fraud of criminalizing cainnabis is being exposed as they cannot maintain cannabis has accepted medical use any longer. DEA and other groups continue to demand Cannabis remain Schedule 1 substance considered dangerous and non-medical, until they can do further studies.

pipeline said:
www.marijuanamoment.net

Feds Release Marijuana Documents, Confirming Schedule III Recommendation Based On ‘Accepted Medical Use’

The U.S. government has released hundreds of pages of documents related to its ongoing review of marijuana’s status under federal law, officially confirming for the first time that health officials have recommended the Drug Enforcement Administration (DEA) place cannabis in Schedule III of the...
www.marijuanamoment.net www.marijuanamoment.net

This is big news because it exposes the open fraud of the authorities demanding cannabis remain a Schedule 1 substance.
Click to expand...

pipeline said:
"Evidence shows that some individuals are taking marijuana in amounts sufficient to create a hazard to their health and to the safety of other individuals and the community. However,

7 evidence also exists showing that the vast majority of individuals who use marijuana are doing so in a manner that does not lead to dangerous outcomes to themselves or others."
Click to expand...

pipeline said:
There are numerous industries making products for the cannabis consumers. From Zippo to Boveda to Premier Promix media, fertilizer companies, restaurants, harvesting equipment. Cannabis is becoming more and more accepted. It said in the release,

"In this document, the term “marijuana” will be used to refer to Cannabis sativa L., to be responsive to language of the CSA definition of “marihuana” or “marijuana” and its listing as the Schedule I drug class that is subject of this evaluation. The present evaluation of marijuana discusses the scientific and medical information relative to each of the eight factors, presents

5 findings in the three required areas (abuse potential, CAMU, and safety or dependence liability) and makes a recommendation regarding the scheduling of marijuana. It is important to note that this evaluation is necessarily limited in scope and depth to those preclinical, clinical, and epidemiological data that are directly related to determining the abuse potential, physical dependence, and CAMU of marijuana in response to the eight factors described in the CSA. As such, this assessment is comprehensive, but is not exhaustive or encyclopedic. Extensive reviews of marijuana and cannabinoids are publicly available in papers published in the scientific and medical literature, as well as from federal entities such as NIDA and the Congressional Research Service, from professional medical associations, and from the National Academies of Science, Engineering and Medicine (NASEM). The current review is largely focused on modern scientific considerations on whether marijuana has a CAMU and on new epidemiological data related to abuse of marijuana in the years since the 2015 HHS 8FAs on marijuana. In the epidemiological analyses below regarding prevalence of marijuana abuse and associated harms, evaluations included comparators such as heroin (Schedule I), fentanyl (Schedule II), oxycodone (Schedule II), hydrocodone (Schedule II), cocaine (Schedule II), ketamine (Schedule III), benzodiazepines (Schedule IV), zolpidem (Schedule IV), tramadol (Schedule IV), and alcohol (FDA Office of Surveillance and Epidemiology, 2023). Each individual epidemiological database evaluated a specific group of drugs and not every comparator was evaluated under each database. It should be noted that although alcohol is well known to be abused, it was explicitly exempted from control under the CSA when it was enacted. Typically, substances that are not controlled under the CSA are not utilized as comparator drugs for scheduling placement considerations because they may not have been formally evaluated for abuse potential in standard preclinical and clinical abuse-related studies. However, alcohol is included in the analyses because of its extensive availability and use in the United States, which is also observed for nonmedical use of marijuana (also known as recreational use of marijuana). After assessing all available preclinical, clinical, and epidemiological data, FDA recommends that marijuana be rescheduled from Schedule I into Schedule III of the CSA. Schedule III drugs are classified as having a potential for abuse less than the drugs or other substances in schedules I and II, a currently accepted medical use in treatment in the United States, and moderate or low physical dependence or high psychological dependence that may result from their use. NIDA concurs with this recommendation."
Click to expand...

pipeline said:
Currently Accepted Medical Use of Marijuana To inform its scheduling recommendation, HHS has conducted an evaluation of whether marijuana has a CAMU for purposes of scheduling under the CSA, 21 U.S.C. § 812(b). Such an evaluation is one of the findings relevant to the placement of a substance in one of five drug control “schedules” set forth in 21 U.S.C. § 812(b). In evaluating CAMU when considering whether to recommend rescheduling of marijuana, HHS (acting through the FDA and NIDA) applied a two-part test (hereinafter, “CAMU test”) that takes into account the current widespread medical use of marijuana under the supervision of licensed HCPs under state-authorized programs. Under Part 1 of the CAMU test, OASH considered whether there is widespread current experience with medical use of marijuana in the United States by licensed HCPs operating in accordance with implemented state-authorized programs, where such medical use is recognized by entities that regulate the practice of medicine under these state jurisdictions.

Part 2 of the CAMU test evaluated whether there exists some credible scientific support for at least one of the medical conditions for which the Part 1 test is satisfied. FDA’s evaluation in Part 2 is not meant to be, nor is it, a determination of safety and efficacy under the Federal Food, Drug, and Cosmetic Act’s (FD&C Act’s) drug approval standard for new human or animal drugs. Rather, the two-part test is to determine whether a substance, in this case marijuana, has a CAMU for purposes of drug scheduling recommendations and placement in a drug schedule consistent with criteria set forth in 21 U.S.C. 812(b).

In the evaluation and assessment under Part 1 of the CAMU test, OASH found that more than 30,000 HCPs are authorized to recommend the use of marijuana for more than six million registered patients, constituting widespread clinical experience associated with various medical conditions recognized by a substantial number of jurisdictions across the United States. For several jurisdictions, these programs have been in place for several years, and include features that actively monitor medical use and product quality characteristics of marijuana dispensed. OASH, through the Assistant Secretary for Health, concluded that, taken together, the findings from Part 1 warranted an FDA assessment under Part 2 of the CAMU test to determine if there exists credible scientific support for the use of marijuana for at least one of the medical conditions identified by OASH under Part 1.

25 FDA conducted Part 2 of the CAMU test for seven indications, based in part on OASH’s findings under Part 1 of the CAMU test9 and in part on FDA’s own analysis of the landscape in which marijuana is currently used medically, including information from state-authorized programs on how and to what extent marijuana is being utilized for medical purposes. The seven indications are: anorexia,10 anxiety,11 epilepsy, inflammatory bowel disease (IBD), nausea and vomiting, pain, and post-traumatic stress disorder (PTSD). FDA’s evaluation under Part 2 of the CAMU test was based on systematic reviews of studies investigating the safety and effectiveness of marijuana, relevant professional societies’ position statements, data from state medical marijuana programs and United States national surveys, and the labeling of FDA-approved products relevant to the analysis. In evaluating whether there exists some credible scientific support under

Part 2 of the CAMU test for a particular use, factors considered in favor of a positive finding included whether: 1) favorable clinical studies of the medical use of marijuana, although not necessarily adequate and well-controlled clinical studies that would support approval of a NDA, have been published in peer-reviewed journals and/or 2) qualified expert organizations (e.g., academic groups, professional societies, or government agencies) have opined in favor of the medical use or provided guidance to HCPs on the medical use. Factors considered that weigh against a finding that Part 2 of the CAMU test is met included whether: 1) data or information indicate that medical use of the substance is associated with unacceptably high safety risks for the likely patient population, e.g., due to toxicity concerns; 2) clinical studies with negative efficacy findings for the medical use of marijuana have been published in peer reviewed journals; and/or 3) qualified expert organizations (e.g., academic or professional societies, government agencies) recommend against the medical use of marijuana (based on the available data at the time of their position statement). Our review of the available information identified mixed findings of effectiveness across indications, ranging from data showing inconclusive findings to considerable evidence in favor of effectiveness, depending on the source. The largest evidence base for effectiveness exists for marijuana use within the pain indication (in particular, neuropathic pain). For the pain indication, a systematic review of scientific and medical literature was conducted this year by the

University of Florida (UF) under contract with FDA. UF epidemiologists identified some data supporting effectiveness of marijuana, including some within their own meta-analysis; however, they ultimately concluded the results are inconclusive or mixed. FDA also conducted a separate review of published scientific reviews. Several of those reviews drew conclusions similar to UF. In contrast, numerous other systematic reviews concluded that there exists some level of evidence supporting the use of marijuana for painful conditions. Other reviews, such as the (National Academies of Sciences & Medicine, 2017), concluded there was “substantial evidence”12 supporting the use of cannabis products relevant to this review for pain. The Agency for Healthcare Research and Quality’s (AHRQ) living systematic review has concluded that there is some support for the use of marijuana-related products in the treatment of pain, but overall concluded these effects were small and the increased risk of dizziness, nausea, and sedation may limit the benefit. UF evaluated other therapeutic conditions mentioned above, i.e., anorexia, anxiety, epilepsy, inflammatory bowel disease (IBD), nausea, and PTSD, employing a similar systematic review of scientific and medical literature. UF found that there is low- to moderate-quality evidence13 supporting the use of marijuana as medical treatment for outcomes in anorexia, nausea and vomiting, and PTSD. However, FDA review of systematic reviews showed mixed results for these indications. In particular, FDA found that the potential for psychiatric adverse events associated with treating PTSD with marijuana may be more substantial than any limited benefit in observational studies.

Although UF did not conclude that there was evidence in support of the effectiveness of marijuana in IBD, both their review and other systematic reviews found some benefit with respect to subjective symptoms in this condition. With regard to epilepsy and anxiety, both UF’s review and FDA’s review of other systematic reviews did not find support for marijuana providing benefit in the treatment of these conditions. Where positive results on effectiveness outcome measures were found, the effects and the quality of evidence were generally in the low-to-moderate range. UF did not find high quality evidence supporting worsening of outcomes in any indication. None of the evidence from the systematic reviews included in our CAMU Part 2 analysis identified any safety concerns that would preclude the use of marijuana in the indications for which there exists some credible scientific support for its therapeutic benefit. The clinical safety data identified in the literature from controlled trials were generally consistent between sources but limited in the rigor of safety reporting. The vast majority of the observational studies evaluated in the context of medical use were excluded from the final synthesis of evidence due to concerns regarding their quality (only one observational study for the anxiety indication and one for the PTSD indication were included). Generally, data on safety from both clinical trials and observational studies were scarce. Literature shows marijuana has more AEs when compared to a placebo or active control group, however, typically in the mild to moderate severity range. Severe AEs were uncommon.27

FDA also reviewed results from state reporting data from 37 states with medical marijuana programs and surveys of patients using marijuana in Maryland and Minnesota, which had data available for review. Surveys of patients using marijuana in these two states found most patients did not report any side effects and those that did report side effects mostly described them as mild. Neither state’s databases included patients who chose to stop using marijuana, which may result in an overestimation of positive experiences. To date, real-world data sources available to FDA, in general, lack the necessary elements to identify the exposure (i.e., marijuana), to distinguish the reason for use (medical vs. recreational) and, if applicable, the condition that prompted its medical use, and/or to permit sound inferential analyses. Therefore, they were not included in this review.

Data from United States national surveys, in general, lacked details on patient characteristics and factors that prompted the use of marijuana for medical purposes, and data collection for these surveys was impacted by the coronavirus disease of 2019 (COVID-19) pandemic. Despite these limitations, these data suggested that medical use of marijuana increases as age increases. Only data from one survey provided information on the intended indication for use, suggesting that individuals often use marijuana to improve or manage conditions such as depression, anxiety, PTSD, pain, headaches or migraines, sleep disorders, nausea and vomiting, lack of appetite, and muscle spasms, but only approximately half of them reportedly had ever asked a healthcare professional for a recommendation to use medical marijuana. Additionally, although the safety data obtained from use in a medical context are considered to be the most relevant for the CAMU analysis, FDA evaluated the safety of marijuana in the nonmedical setting to inform the potential for more severe outcomes.

Specifically, FDA evaluated safety outcomes related to marijuana use in the setting of nonmedical use, use of uncertain intent, and unintentional exposure through a variety of epidemiological data sources and in relation to several comparator substances controlled under the CSA, including drugs in Schedule I: heroin (an illicit opioid drug); Schedule II: hydrocodone and oxycodone (approved opioid prescription drug products), cocaine and fentanyl (largely illicitly produced drugs in the nonmedical use setting, although there are approved prescription drugs); Schedule III: ketamine (an approved prescription drug); and Schedule IV: zolpidem, benzodiazepines, and tramadol (approved prescription drugs) (FDA Office of Surveillance and Epidemiology, 2023). The comparative data demonstrate that, even in the context of nonmedical use, marijuana has a less concerning overall safety profile relative to the comparators for a number of important outcomes (e.g., single substance use overdose death, hospitalizations). However, in young children, population-adjusted rates of ED visits and hospitalizations involving marijuana poisoning were higher than heroin, cocaine, and benzodiazepines for the periods studied. Of note, some of the comparator substances are approved for use in conditions similar to the indications for which marijuana was evaluated in the CAMU analysis (e.g., opioids for pain, benzodiazepines for anxiety-related conditions). FDA also considered position statements from professional organizations relevant to the indications discussed. The vast majority of professional organizations did not recommend the use of marijuana in their respective specialty; however, none specifically recommended against28

it, with the exception of the American Psychiatric Association (APA), which stated that marijuana is known to worsen certain psychiatric conditions. On balance, the available data indicate that there is some credible scientific support for the use of marijuana in the treatment of pain, anorexia related to a medical condition, and nausea and vomiting, with varying degrees of support and consistency of findings. Additionally, no safety concerns were identified in our review that would indicate that medical use of marijuana poses unacceptably high safety risks for the indications where there is some credible scientific evidence supporting its therapeutic use. Conclusions of CAMU Based on the totality of the available data, we conclude that there exists some credible scientific support for the medical use of marijuana in at least one of the indications for which there is widespread current experience in the United States, as identified by OASH under Part 1 of the CAMU test.

Seven indications were selected for evaluation under Part 2 of the CAMU test based on conclusions from Part 1 of the CAMU test as well as the FDA’s analysis of the landscape of medical use of marijuana. The indications evaluated anorexia related to a medical condition, anxiety, epilepsy, inflammatory bowel disease, nausea and vomiting (e.g., chemotherapy-induced), pain, and post-traumatic stress disorder. The analysis and conclusions on the available data are not meant to imply that safety and effectiveness have been established for marijuana that would support FDA approval of a marijuana drug product for a particular indication. However, the available data do provide some level of support for the way marijuana is being used in clinical practice. Thus, based on the widespread HCP experience and the extent of medical use evaluated by OASH under the Part 1 test, and an evaluation of available credible scientific support described herein for at least some therapeutic uses identified in the Part 1 test, we find that that, for purposes of the drug scheduling criteria in 21 U.S.C. 812(b), marijuana has a CAMU in the United States for: anorexia related to a medical condition; nausea and vomiting (e.g., chemotherapy-induced); and pain.
Click to expand...
 
pipeline

pipeline

Cannabotanist
ICMag Donor
Veteran

full

​

Psalm 78 NKJV​

​

God’s Kindness to Rebellious Israel​

A Contemplation[a] of Asaph.​

78 Give ear, O my people, to my law;
Incline your ears to the words of my mouth.
2 I will open my mouth in a parable;
I will utter [b]dark sayings of old,
3 Which we have heard and known,
And our fathers have told us.
4 We will not hide them from their children,
Telling to the generation to come the praises of the Lord,
And His strength and His wonderful works that He has done.

5 For He established a testimony in Jacob,
And appointed a law in Israel,
Which He commanded our fathers,
That they should make them known to their children;
6 That the generation to come might know them,
The children who would be born,
That they may arise and declare them to their children,
7 That they may set their hope in God,
And not forget the works of God,
But keep His commandments;
8 And may not be like their fathers,
A stubborn and rebellious generation,
A generation that did not [c]set its heart aright,
And whose spirit was not faithful to God.

9 The children of Ephraim, being armed and [d]carrying bows,
Turned back in the day of battle.
10 They did not keep the covenant of God;
They refused to walk in His law,
11 And forgot His works
And His wonders that He had shown them.

12 Marvelous things He did in the sight of their fathers,
In the land of Egypt, in the field of Zoan.
13 He divided the sea and caused them to pass through;
And He made the waters stand up like a heap.
14 In the daytime also He led them with the cloud,
And all the night with a light of fire.
15 He split the rocks in the wilderness,
And gave them drink in abundance like the depths.
16 He also brought streams out of the rock,
And caused waters to run down like rivers.

17 But they sinned even more against Him
By rebelling against the Most High in the wilderness.
18 And they tested God in their heart
By asking for the food of their fancy.
19 Yes, they spoke against God:
They said, “Can God prepare a table in the wilderness?
20 Behold, He struck the rock,
So that the waters gushed out,
And the streams overflowed.
Can He give bread also?
Can He provide meat for His people?”

21 Therefore the Lord heard this and was furious;
So a fire was kindled against Jacob,
And anger also came up against Israel,
22 Because they did not believe in God,
And did not trust in His salvation.
23 Yet He had commanded the clouds above,
And opened the doors of heaven,
24 Had rained down manna on them to eat,
And given them of the [e]bread of heaven.
25 Men ate angels’ food;
He sent them food to [f]the full.

26 He caused an east wind to blow in the heavens;
And by His power He brought in the south wind.
27 He also rained meat on them like the dust,
Feathered fowl like the sand of the seas;
28 And He let them fall in the midst of their camp,
All around their dwellings.
29 So they ate and were well filled,
For He gave them their own desire.
30 They were not [g]deprived of their craving;
But while their food was still in their mouths,
31 The wrath of God came against them,
And slew the stoutest of them,
And struck down the choice men of Israel.

32 In spite of this they still sinned,
And did not believe in His wondrous works.
33 Therefore their days He consumed in futility,
And their years in fear.

34 When He slew them, then they sought Him;
And they returned and sought earnestly for God.
35 Then they remembered that God was their rock,
And the Most High God their Redeemer.
36 Nevertheless they flattered Him with their mouth,
And they lied to Him with their tongue;
37 For their heart was not steadfast with Him,
Nor were they faithful in His covenant.
38 But He, being full of compassion, forgave their iniquity,
And did not destroy them.
Yes, many a time He turned His anger away,
And did not stir up all His wrath;
39 For He remembered that they were but flesh,
A breath that passes away and does not come again.

40 How often they provoked[h] Him in the wilderness,
And grieved Him in the desert!
41 Yes, again and again they tempted God,
And limited the Holy One of Israel.
42 They did not remember His [i]power:
The day when He redeemed them from the enemy,
43 When He worked His signs in Egypt,
And His wonders in the field of Zoan;
44 Turned their rivers into blood,
And their streams, that they could not drink.
45 He sent swarms of flies among them, which devoured them,
And frogs, which destroyed them.
46 He also gave their crops to the caterpillar,
And their labor to the locust.
47 He destroyed their vines with hail,
And their sycamore trees with frost.
48 He also gave up their cattle to the hail,
And their flocks to fiery [j]lightning.
49 He cast on them the fierceness of His anger,
Wrath, indignation, and trouble,
By sending angels of destruction among them.
50 He made a path for His anger;
He did not spare their soul from death,
But gave [k]their life over to the plague,
51 And destroyed all the firstborn in Egypt,
The first of their strength in the tents of Ham.
52 But He made His own people go forth like sheep,
And guided them in the wilderness like a flock;
53 And He led them on safely, so that they did not fear;
But the sea overwhelmed their enemies.
54 And He brought them to His holy border,
This mountain which His right hand had acquired.
55 He also drove out the nations before them,
Allotted them an inheritance by [l]survey,
And made the tribes of Israel dwell in their tents.

56 Yet they tested and provoked the Most High God,
And did not keep His testimonies,
57 But turned back and acted unfaithfully like their fathers;
They were turned aside like a deceitful bow.
58 For they provoked Him to anger with their high places,
And moved Him to jealousy with their carved images.
59 When God heard this, He was furious,
And greatly abhorred Israel,
60 So that He forsook the tabernacle of Shiloh,
The tent He had placed among men,
61 And delivered His strength into captivity,
And His glory into the enemy’s hand.
62 He also gave His people over to the sword,
And was furious with His inheritance.
63 The fire consumed their young men,
And their maidens were not given in marriage.
64 Their priests fell by the sword,
And their widows made no lamentation.

65 Then the Lord awoke as from sleep,
Like a mighty man who shouts because of wine.
66 And He beat back His enemies;
He put them to a perpetual reproach.

67 Moreover He rejected the tent of Joseph,
And did not choose the tribe of Ephraim,
68 But chose the tribe of Judah,
Mount Zion which He loved.
69 And He built His sanctuary like the heights,
Like the earth which He has established forever.
70 He also chose David His servant,
And took him from the sheepfolds;
71 From following the ewes that had young He brought him,
To shepherd Jacob His people,
And Israel His inheritance.
72 So he shepherded them according to the integrity of his heart,
And guided them by the skillfulness of his hands.
 
You must log in or register to reply here.

Latest posts

Latest posts

Top